Free Trial

Sangamo Therapeutics (SGMO) SEC Filings & 10K Form

Sangamo Therapeutics logo
$0.92 -0.10 (-9.75%)
Closing price 03/3/2025 04:00 PM Eastern
Extended Trading
$0.94 +0.02 (+2.12%)
As of 03/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Sangamo Therapeutics SEC Filings

DateFilerForm TypeView
02/26/2025
4:30 PM
Macrae Sandy (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2025
4:31 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2025
4:32 PM
Sangamo Therapeutics (Issuer)
Willoughby Scott B. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2025
4:32 PM
Dubois-Stringfellow Nathalie (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2025
4:33 PM
Davis Gregory D (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/06/2025
7:13 AM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2025
5:47 PM
Sangamo Therapeutics (Subject)
WASATCH ADVISORS LP (Filed by)
Form SCHEDULE 13G/A
12/30/2024
3:23 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/09/2024
8:27 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/26/2024
3:07 PM
Macrae Sandy (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/26/2024
3:08 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2024
11:15 PM
Sangamo Therapeutics (Filer)
Form EFFECT
11/12/2024
3:53 PM
Sangamo Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
11/04/2024
12:54 PM
Sangamo Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
10/28/2024
3:11 PM
Davis Gregory D (Reporting)
Sangamo Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
08/27/2024
3:36 PM
Macrae Sandy (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/27/2024
3:37 PM
Dubois-Stringfellow Nathalie (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/27/2024
3:37 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/27/2024
3:38 PM
Pooler Amy (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/27/2024
3:38 PM
Sangamo Therapeutics (Issuer)
Willoughby Scott B. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/16/2024
5:40 PM
BIOGEN INC. (Filed by)
Sangamo Therapeutics (Subject)
Form SC 13G/A
08/15/2024
3:34 PM
Sangamo Therapeutics (Issuer)
Willoughby Scott B. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/24/2024
3:05 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/08/2024
3:32 PM
BlackRock Inc. (Filed by)
Sangamo Therapeutics (Subject)
Form SC 13G/A
06/13/2024
3:42 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
4:10 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/29/2024
4:18 PM
Dubois-Stringfellow Nathalie (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/29/2024
3:57 PM
Duraibabu Prathyusha (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/29/2024
4:00 PM
Pooler Amy (Reporting)
Sangamo Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/19/2024
3:14 PM
Sangamo Therapeutics (Filer)
Form ARS
03/25/2024
4:04 PM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/13/2024
6:55 AM
Sangamo Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/13/2024
6:47 AM
Sangamo Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:SGMO) was last updated on 3/4/2025 by MarketBeat.com Staff
From Our Partners